CEO Board Update

Seth Berkley, MD 6 June 2018, Geneva, Switzerland





www.gavi.org

KEY DEVELOPMENTS IN OUR GLOBAL LANDSCAPE





Strategy update

6-7 June 2018

Re-emergence of Ebola in DRC

- Ninth DRC outbreak since discovery in 1976
- 56 reported cases, 25 reported deaths
- Vaccine doses available via Gavi Advance Purchase Commitment (APC)
- First use of vaccine since the 2014 West African outbreak
- First dose given 13 days after outbreak declared, 1,199 vaccinated to date
- Gavi provided US\$1m for operational costs to deploy vaccine
 Board meeting







Strategy update

Previous Board decisions

Meeting agenda

Ebola in DRC – historical & current





Ntondo




Board meeting 6-7 June 2018 Wangata



Following

First #ebola vaccination done In Mbandaka, DRC Guillaume Ngoie Mwamba, EPI manager leads the way #VaccinesWork





Milestones to Ebola vaccine availability

- 2014-2016 West African outbreak •
- **2014** Board approved funding envelope for Ebola •
- 2015 Gavi offered an APC to all manufacturers that had a vaccine in Phase I+
- Late 2015 Gavi Board approved one agreement, prepayment to Merck contingent on their commitment to:
 - Apply for WHO Emergency Use Assessment Listing by end 2015
 - Ensure 300,000 doses of investigational vaccine available •
 - Submit for licensure by end of 2017
- More than 17,500 doses deployed in DRC ٠

Board meeting 6-7 June 2018

Congo (DRC)?


Continued threat of epidemic diseases without vaccines



THIRUVANANTHAPURAM: With 10 deaths due to the deadly Nipah virus being

Key epidemic diseases without licensed vaccines

Recurrence of Nipah Kerala, India, 20 deaths confirmed



Nature article January 2017 quoting CEPI data, D.Butler Billion-dollar project aims to prep vaccines before epidemics hit



Key developments

Previous Board decisions

CEPI news

Recent disbursements

US\$37.5m to Themis Bioscience to develop Vaccines against Lassa Fever and MERS (March)

US\$56m to Inovio to develop DNA Vaccines against Lassa fever and MERS (April)

US\$10.4m IAVI partnership to develop a VSV vaccine candidate against Lassa fever (May)



CEPI Partners with the International AIDS Vaccine Initiative to Advance Lassa Fever Vaccine Development

The Coalition for Epidemic Preparedness Innovations (CEPI) and the International AIDS Vaccine Initiative (IAVI) announced a partnership today to develop a new vaocine candidate against Lassa fever virus with the goal of creating a stockpile to address future outbreaks.



The partnership will support the development of IAVI's replicating viral vector-based Lassa vaccine candidate. /VSVAG-LASV-GPC. CEPI · provide US\$10.4 million to support the first phase of the project, with options to invest up to a total of US\$64.9 milli over fine years (including -checking). CERIE is consulted


This meeting

 Board will discuss epidemic VIS

> Norway exploring use of IFFIm to frontload their support for CEPI




A Grand Challenge for Universal Flu vaccination



- Funding announced from • **BMGF & Google**
- US\$ 12m seed funding with individual grants for proof of concept work



Safeguarding -significant issue for the development sector



What does Gavi already have in place? Comprehensive policies, code of conduct, training for managers, Staff Council, Ombudsman, Whistleblower hotline

What more are we doing?

Revising wording in contracts & policies, rolling out training to all employees, looking for synergies with partners



Meeting agenda

Alliance update

Improved SDG indicators adopted



Immunisation Indicators: 2 Other health Indicators: 25 Other Indicators: 205

> Improved SD adopted: 3.b.1 Propo covered by national pro Includes DT UHC indicato

'Over half a billion of the world's children live in 64 countries that <u>lack sufficient data</u> for us even to assess if they are on or off track for at least *two-thirds* of all childrelated SDG indicators'

Even for early days, the outlook the report reveals **3.8.1** Coverage

Immunisation included as a tracer interve

PROGRESS FOR EVERY CHILD IN THE SDG ERA

unicef @

fair chance. environment protection learning survive+thrive

UNICEF March 2018



Meeting agenda



Several initiatives to simplify health architecture



'We believe that all global efforts should be developed further into one joint 'Global Action Plan for Health Lives for All'.'

'propose that WHO ... guides – together with the heads of the other relevant organisations – the elaboration of such a plan to be presented by October 2018 at the WHS'

globally and in-country – would enable improved delivery of results, particularly on: health financing; health systems strengthening; results frameworks; monitoring and evaluation; risk management; partner engagement; and global public goods'

6-7 June 2018



Strategy update


Previous Board decisions

Meeting agenda

Alliance update

World Health Assembly 2018





Changes in Alliance leadership



Henrietta H. Fore Executive Director UNICEF



Cyrus Ardalan IFFIm Chair



Meeting agenda

Alliance update

Ministers of Finance meeting



An opportunity for Ministers to share their experiences & approaches to health budgeting and transitions



Gavi recognised by AidData: 'Listening to Leaders' perceived helpfulness of development partners

AIDDATA Change 2014 to 2017 Adjusted 2014 Survey Rank* (Measuring 2004 2016) 2017 Survey Rank Net Change Measuring 2010-2015 GAVI Alliance** GAVI Alliance 0 IMF 0 +2 World Bank UNICEF GEF** World Bank -1 UNICEF 5. European Union +3 IDB +1 Denmark 6. IDB Global Fund +3 European Union United States +5 8. 8. AfDB (Africa) Sweden +7 10. Global Fund 10. UNDP +5

Listening to Leaders 2018

Which partners receive the highest marks for helpfulness in implementation?

I. Global Alliance for Vaccines and Immunization (GAVI)	85.4%
. International Monetary Fund (IMF)	85.1%
United Nations Children's Fund (UNICEF)	83.9%
1. World Bank	83.7%
5. European Union	82.9%
5. Inter-American Development Bank (IDB)	82.8%
7. Global Fund to Fight AIDS, Tuberculosis and Malaria	82.5%
3. United States	81.1%
 African Development Bank (AfDB) 	78.6%
10. United Nations Development Program (UNDP)	77.7%

Helpful defined as being of assistance in implementing policy changes



Meeting agenda

Alliance update

The road to Mid-Term Review

MONDAY , MAY 28 2018 Forex Advertising

🕈 🕑 🛛 Search

THE GULF TIME

EMIRATES BUSINESS

UAE TO HOST GAVI 2018 MID-TERM REVIEW IN DEC

🛔 Admin 🕐 April 18, 2018 🖿 Local News

Abu Dhabi / WAM

Reem bint Ibrahim AI Hashimy, Minister of State for International Cooperation, announced that the UAE will host the Gavi 2018 mid-term review. The high-level conference will be hele in Abu Dhabi on December 10-11, and will lay out a vision for the future of the Gavi model, providing an opportunity to take stock of Gavi's performance halfway through the current strategic period 2016-2020.

The conference will outline new ways of working with partners, allowing Gavi to forge new aliances with private sector and adopt transformative solutions to advance the global immunisation agenda. At its 2015 replenishment conference in Berlin, Gavi committed to immunise 300mn additional kids in 2016-2020 strategic period, saving five to six million lives, and securing economic benefits of \$80-100 billion globally.

The mid-term review will assess Gavi's progress towards this ambitious goal. It will also be an opportunity to celebrate the 10th anniversary of Gavi's trailblasing innovative finance instruments, such as vaccine bonds through International Financing Facility for Immunisatio and Advance Market Commitment for pneumococcal vaccine. UAE was the first Gavi door from MENA region, making its first commitment of \$33 million to Gavi in 2011. Our mid-term review will take place in the United Arab Emirates in December this year

As one of @Gavi's first donors from the region, the #UAE is a committed and long-standing partner.

Find out more Now.ly/sKqk30jyps9 – with @UAEAid #UAEAid

Gavi 🏠 #VaccinesWork

1:36 am - 29 Apr 2018

gotlife.gavi.org

Board meeting 6-7 June 2018

Got vaccines? \Got life!











With innovation being integral to the UAE Foreign Assistance policy, we look forward to continuing to work together with Gavi to support innovative health approaches that make a real difference to developing countries, ensuring that every child is protected with life-saving vaccines.

Meeting agenda

Alliance update

Mid-Term Review: objectives

- Accountability exercise midway through our fiveyear strategy period
- Culminates in a highprofile event in Q3/Q4 in 2018

2016



2018

- report back to donors on progress towards commitments made in the 2016-2020 Investment Opportunity
- secure continued support from donors and partners
- discuss Gavi progress, achievements and challenges
- lay the foundations for next replenishment

Work to support gender equity

Gavi given top ranking

Global Health 50/50: review of gender-related policies at 140 global health organisations

Looking at programmatic work & workplace balance

Gavi's Gender Policy is an important consideration in programmatic work – to support our Coverage & Equity agenda and reaching the 5th child






UPDATE ON OUR STRATEGY





Gavi making progress on its journey to build a culture of datadriven continuous performance improvement



Opport vaccine covera no M&E

Regular data-driven monitoring driving performance improvement including:

- Strategy Progress Update
- Joint Appraisals
 - Grant Performance Frameworks
 - PEF framework
 - Secretariat Corporate Performance Management



Experience tracking 2016-20 strategy progress revealed four types of issues with some indicators







Data quality and availability of some indicators limited



Partial alignment of some indicators with the Alliance's strategies and investments

Guiding principles for revision included strong rationale for change and maintaining same level of ambition in targets


2016–2020 INDICATORS

STRATEGY PROGRESS

Strategy update

Previous Board decisions

- 5 ON TRACK
- 2 MODERATE DELAYS / CHALLENGES
- 2 SIGNIFICANT DELAYS / CHALLENGES
- 2 TRACKING TREND ONLY/ DATA INCONCLUSIVE




Meeting agenda

22 introductions achieved so far in 2018 - on track for 52 target by year end



11 delays in 2018:


- 4 due to weak financial management systems
 (2 in Gambia, 2 in Togo)
- 6 due to country readiness issues (2 in Chad, Côte d'Ivoire, Kenya, Niger)
- 1 due to unresolved audit issue (Cameroon)



Time to disburse above target, driven by higher risk countries 2 Strengthen systems

Time to disburse (months)

Time to disburse by country profile (in months)



Strengthen systems

Targeting and tailoring Gavi's HSS Afghanistan - fragile country, 65% penta 3 coverage

Lack of access to reliable services Reasons for I

449 of 536 health sub-centres not offering immunisation

Gender-related barriers 75% of vaccinators male

Inadequate demand, understanding of, and confidence in, vaccines



- Add immunisation in 310 sub-centres^b including equipping with cold chain
- Support 15 mobile health teams for
- Recruit 300 more female vaccinators
 target of 40% of vaccinators female vaccinators in 2878 villages
 Work with 14,400 religious leaders to raise awareness / demand
- Build communication capacity of health workers / school teachers
- Toll free information line in two languages half staff are female


Source: WUENIC, July 2017; Afghanistan National Immunisation Coverage Survey, 2013

Meeting agenda


Alliance update

DRC challenge: routinely reaching most children with immunisation but, less than half fully immunised 2 Strengthen systems

Penta 1 coverage, National average 81%



94% of children have received at least one vaccine




Source: DHS 2013-14

Strengthen systems

Massive disparities in availability of immunisation sessions

Frequency of immunisation sessions




Meeting agenda

Alliance update

Strengthen systems

Health zones averaging a stock out every 6 weeks but large variation across the country

Number of stockout occurrences in 2017 by Zone de Santé



Analysis performed for 6 antigens : BCG, Penta, VPO, VAR, VAA and PCV

Strengthen systems

Installations of Cold Chain Equipment in first 2 countries 11 deployments to be complete in 2018

2018 CCEOP deployment plan

2 deployments complete or ongoing

- Haiti (complete)
- DRC (ongoing)

> 24,800 refrigerators installed by end of 2018

> 72.200 by 2022

9 deployments to be

complete by end of 2018

- Pakistan
- Kenya
- Djibouti
- S. Sudan
- Niger
- Sierra Leone
- Liberia •
- Uganda
- Malawi •

23 deployments to start in 2018 and continue until 2022

Ethiopia

Somalia

Rwanda

Solomon

Islands

PNG

2

- Guinea
- Togo ٠
- Tanzania
- Cameroon •
- Fritrea
- Vietnam
- Myanmar •
- Uzbekistan **Burkina Faso**
- Senegal
- Madagascar

- Kyrgyzstan CAR
 - Côte d'Ivoire
 - Gambia
 - Nepal
 - Benin •
 - Mauritania



Improve sustainability

Majority of transitions on track, 3 higher risk countries proposed to receive post-transition support



4 8 countries transitioned end of 2017

43 of which are high-risk countries with specific approach for post-transition as requested by PPC

9 countries in accelerated transition

Strategy update

Previous Board decisions

Meeting agenda

Alliance update

Gavi's theory of change









Meeting agenda

Alliance update

Country transition from Gavi support data (DTP3 coverage comparing 2016 to 1999)




Country transition from Gavi support – new vaccine introductions (Pentavalent, PCV, Rotavirus, HPV, up to 2017)



Country transition from Gavi support data (US\$ per child on immunisation comparing pre & post transition)

Annual financing by country per child (US\$):




Meeting agenda


Market shaping indicators – 2017




1 Number of vaccine markets with sufficient & uninterrupted supply of appropriate vaccines



3 Number of products with improved characteristics procured



2 Weighted average price per course: Pentavalent, Rotavirus and Pneumococcal



4 Number of Gavi vaccine markets with moderate or high healthy market dynamics

Vaccine markets	Gavi vaccine markets' level of healthy market dynamics	
	2016	2017
Pentavalent	Moderate	Moderate
PCV	Low	Moderate
Yellow Fever	Low	Moderate
Cholera	Low	
JE	Low	
Meningitis A	Low	
MR	Low	
Measles	Low	
Rotavirus	Low	
HPV	Moderate	None
IPV	None	None



2016–2020 INDICATORS

ALLIANCE PROGRESS

Strategy update


Previous Board decisions

- 9 ON TRACK
- 2 MODERATE DELAYS / CHALLENGES
- **3** SIGNIFICANT DELAYS / CHALLENGES
- TRACKING TREND ONLY
- **3** NO UPDATE





No substantial changes to Gavi's overall risk profile since last Risk & Assurance Report




REPORTING BACK ON PREVIOUS BOARD DECISIONS





Alliance update

AEFI Reports





Key developments


Previous Board decisions

Meeting agenda

Alliance update

AEFI Reports (Gavi 68 countries highlighted)

Gavi has invested in Vaccine safety since 2001





Meeting agenda

Fragility Emergency Refugee Policy has allowed proactivity & to reach groups we didn't before in 7 countries to date



Examples - flexibilities from FER Policy

Emergencies: support for additional operational costs for RI through alternative modalities & additional HSS up to 50% of ceiling

Refugees: host countries may request additional doses of already approved vaccines + broader age / antigen range

Yemen broader antigen introduction & HSS *via* FER. Cholera through stockpile/ICG.



Bangladesh RI among Rohingya refugees *via* FER. Cholera through stockpile/ICG.



Uganda routine vaccine doses for South Sudanese refugees *via* FER.





Syria crisis enters its 8th year

Achieved a great deal

- uninterrupted supply of vaccines contributed to reported improvement in 2017 coverage
 - routine services revitalised in the NW part of Syria
- no new Polio cases since 2017
- cold chain equipment procurement underway

...but it remains a country in crisis

- significant concerns on the spread of measles
- 13.1 million people need assistance
- only 50% of intended aid delivered in 2017
- <50% of health facilities are functional</p>
- Humanitarian Response Plan largely underfunded in 2017

Gavi support ends in December 2018 Board decision to be taken on continued funding, guidance welcome



Haiti

Previous Board decisions

6-7 June 2018


Meeting agenda

Burden of Cholera – Gavi campaigns in 2017

A Annual incidence per 100 000 people

WHA18 Cholera resolution

- Cholera recognised as priority
- Called for enhanced, integrated prevention and response



April 2018 – campaigns

conducted

Plateau

Benue

Yobe


Taraba

Borno

Adamav


Widespread outbreak of YF in Nigeria

April 2018



- No suspected case
- 1-10 suspected cases
- 11-50 suspected cases
- 50-100 suspected cases
- >100 suspected cases

April 2018 – confirmed



- 1-2 confirmed cases
- 3-5 confirmed cases
- >5 confirmed cases

States without any YF immunization activity States completed YF preventative mass vaccine coverage States with YF immunization activity in some LGAs States with confirmed YF and planned RVC in some LGAs States with confirmed YF to have ICG request completed

Oyo

Lanos


amfara

aduna



and the Impact of Vaccination, PLOS Neg Trop Dis, 2018, 12:e0006158.

Gavi considering new investment in strengthening Yellow Fever surveillance and laboratory capacity (*Luanda, Angola*)





Meeting agenda

Alliance update

Progress on implementing Yellow Fever EYE Strategy but significant ways to go



Eliminate yellow fever epidemics by 2026



The Broinsting Volces from Epidemics (EFB) strategy is a global and comprehensive long term (2017-2026) strategy targeting the most indertable constraints, which is adversatigging obtained by balance and ensuring relable vaccine angely by firming a global coalision of partners to predict needs and hape vecice production. The strategy consist of three strategic objectives bulk on lessons learned and is supported by necross-and generation.

OUR VISION

A world without yellow fever epidemics.

OUR MISSION

Coordinate international action and help at-risk countries to prevent yellow fever outbreaks and to prepare for those which might still occur. We aim to minimize suffering, damage and spread by early and reliable detection and a rapid and appropriate response.

Photo could: WHO/Tashi Shimiza

Key competencies for success • Affordable vaccines and sustained vaccine market. • Strong political commitment at global, regional and county

evels. • High level governance with longterm partnerships.

 Synergies with other health programmes and sectors.
 Research and development for better tools and practices.

> World Health Organization

Some movement on applications for introductions / campaigns:

- Campaigns Ghana, DR Congo
- RI Kenya expanding geographic scope
- EYE plan endorsed by AFRO




@EYE regional kick off meeting in Abuja. Yellow fever epidemics reflect not a failure of science but of commitment. @WHO @UNICEF and @gavi launch new strategy to eliminate YF by 2026 @DrTedros @WHOAFRO @MoetiTshidi






Disease burden is strongly underestimated. Only 3-19% of suspected cases are confirmed and serotype identified

Africa's Meningitis belt: 2005 -17 dominant serogroup change



Board meeting 6-7 June 2018

Comparative proportions of serogroup prevalence:



Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. The Lancet Infectious diseases 2017; 17(8): 867-72

Source for 2005-2015:


Source for 2016-2017: Meningitis Weekly Bulletin, Inter country support team – West Africa.



Meeting agenda

Alliance update

Measles outbreaks continue to be a problem despite record low mortality 6 months 09/2017 - 02/2018



Top 10*				
Country	Cases			
India	18515			
Ukraine	6184			
Nigeria	3157			
Serbia	2822			
Pakistan	2048			
Indonesia	1959			
Greece	1740			
Philippines	1684			
China	1567			
Malaysia	1167			

Notes: Based on data received 2018-April *Countries with highest number of cases for the period



 Map production:
 World Health Organization, WHO, 2017. All rights reserved

 Data source:
 IVB Database

Disclaimer:

The boundaries and names shown and the designations used on this map do notimply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps reprisent approximate border lines for which there may not yet be full agreement.




Meeting agenda

Alliance update

Three countries still Polio-endemic, ten Wild Poliovirus cases to date in 2018




GLOBAL



Extensive levels of drug resistance seen in Typhoid

- At least 850 cases in 14 Pakistan districts since 2016
- 1 imported case UK
- 250,000 BMGF & Bharat funded doses allocated
 - 150,000 shipped, 50,000 used
- Pakistan has applied for Gavi support as risk-based campaign & national routine





Alliance update

Reflections from our Board Retreat



• UNDERSTAND THE COVERAGE AND EQUITY CHALLENGE • INTRODUCE AND DISCUSS POSSIBLE THEMES FOR GAVI 5.0-ZOZI-25 STRATEGY PROCESS





.....

HEALTH


Key Coverage & Equity take-aways from Board retreat


- We are making progress in most countries, progress in fragile countries has plateaued
- Appreciation of data & desire to see more subnational information & systematic analysis
- Encouraged Gavi to continue to differentiate support based on each country need, be more flexible and tailor interventions at sub-national level

- Most Board members indicated willingness to accept higher risk appetite in fragile settings
- Immediate follow-up: Changes to HSIS framework and FER policy recommended by PPC



Importance of subnational data







W UNIVERSITY of WASHINGTON

Meeting agenda

Alliance update

Focus on urban immunisation – Pakistan

- Estimated 400,000 under-immunised children living in urban areas in Pakistan, many of whom reside in urban slums
- UNICEF / CSO profile of Karachi & Hyderabad urban slums showed poor immunisation availability for urban poor

- Development of 9 city concept notes for investment & technical assistance
- Pakistan using US\$16M of Gavi HSS to support urban strategy
- Expanded partners to develop an urban roadmap for Karachi & guidance for the engagement of urban CSOs



Urban immunisation

15.7 million under-immunised children live in Gavi-countries

Of these, **6.4 million** live in urban areas

An estimated 40% of underimmunised children are in urban areas

2016 data

Reasons:

•

•

- Urban poor areas often not in data collection & national surveys
 - Due to rapid population growth, public services generally insufficient to meet needs of urban poor communities, increased use of private clinics
 - Developing political will to improve service delivery is complex (e.g. marginalised populations often live in slums, engagement with leadership of municipalities)
 - Urban populations are diverse and often mobile (Kampala's daytime population is 3m during the day but 1m at night due to commuters)



Our journey to Gavi 5.0


'the beauty of success here is that our job is getting a bit more complicated'



Bill Gates, Gavi Partners breakfast, Davos, January 16th 2018



Global number of child deaths per year (by cause of death)



Board meeting

6-7 June 2018



Gavi has started process to define 2021-2025 strategy

How does Gavi finish the job?

18 of 1,000 children will be dying of vaccine-preventable diseases in2020; at current pace, U5 mortalitySDG target will be missed.

How can the Gavi/ immunisation platform be used to accelerate the scale-up of other health interventions?

Immunisation: 8 touchpoints per child in first 9 years of life, 500m touchpoints each year worldwide.



To what extent should Gavi engage in reaching the unreached in MICs?


More than two-thirds of world's poor live in MICs today; more than half of underimmunised in MICs in 2025.


How can Gavi's tools contribute to global health security?

Number of outbreaks has grown steadily from 1980 to 2010, over 3-fold increase.



Non-Gavi MICs paid considerably higher prices per dose in non-mature markets








Non-Gavi MICs lag behind Gavi countries in new vaccine introductions

% of countries with PCV

% of countries with rotavirus





Effective vaccine management

Composite



Composite score of countries: for National, sub-national, lowest distribution and service point for all 9 quality criteria: Storage capacity, maintenance, stock management, vaccine management, information systems, infrastructure, temperature control, vaccine arrival and distribution



AGENDA FOR THIS MEETING





Our Meeting Agenda

Changes to agenda structure

New: Board decisions dashboard

Decision points

- Consent agenda
- Successful transition of Nigeria from Gavi support
- Engagement with countries posttransition
- Vaccine Investment Strategy
- Gavi's engagement in Polio
 eradication



ALLIANCE UPDATE






Board meeting 6-7 June 2018 GALLIP

Alliance Health Survey

While Overall Satisfaction with the partnership has considerably improved, the more emotional dimensions are unchanged



The increase in Overall Satisfaction indicates a positive change in terms of the rational aspects of the partnership. However, perceptions regarding the emotional, experiential aspects such as respect for each other, mutual trust and fairness have remained relatively weak.

Please note: Given the population/sample changes we cannot have a 1:1 comparison of present and past data. This is only an indication of the trend/changes.

10 Copyright © 1994-2000, 2018 Gallup, Inc. All rights reserved

Example Interventions to date

- Alliance leadership engagement plan
- Joint Alliance leadership comms
- Regular Alliance-wide discussions
- Alliance onboarding
 guide
- Alliance directory & connectivity guide



7

4

11

Gender balance

Audit and Finance Committee

Investment Committee

Programme and Policy Committee

60% are women	** ****	İ	0% men		50% of senior management team is female 41% of senior leaders at Gavi are female (CS 5, 6, 7&8) The industry average is 25%* * Grant Thornton: Women in business 2017
	м	F	% M	% F	
Board Members	15	13	54%	46%	
Alternate Board Members	9	9	50%	50%	
Market-Sensitive Decisions Committee	7	7	50%	50%	Governance / Board
Governance Committee	8	4	67%	33%	representation



Board meeting 6-7 June 2018

30%

33%

45%

70%

67%

55%


3

2

9

Meeting agenda

Global Health Campus



Compelling book launch pertinent to our work

FIGHTING Corruption IS Dangerous

The Story Behind the Headlines

NGOZI **OKONJO-IWEALA**





THANK YOU





www.gavi.org